Gnomica develops small‑molecule inhibitors that block bacterial metabolic pathways which support tumor growth, providing a complementary approach to existing cancer therapies. Their platform combines high‑throughput screening, SAR optimization, and preclinical safety profiling to deliver selective agents for pharmaceutical partners targeting the microbiome‑cancer axis.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer therapies largely ignore the role of bacteria that can promote tumor growth, leaving a gap in treatment options that address microbial contributions to oncogenesis.
Solution
Gnomica is creating small‑molecule inhibitors that specifically block bacterial metabolic pathways known to support cancer cell proliferation. By targeting these microbial mechanisms, the compounds aim to complement existing oncology treatments and reduce tumor progression driven by bacterial activity. The approach focuses on preclinical validation of selective inhibitors that can be advanced toward clinical testing for cancer patients.
Target Audience
Primary customers are pharmaceutical companies and oncology research programs seeking novel agents that target the microbiome‑cancer axis.
Features
- Design of chemically optimized small molecules that bind to bacterial enzymes implicated in tumor‑promoting pathways
- High‑throughput screening platform to identify potent and selective bacterial pathway inhibitors
- In‑vitro and in‑vivo preclinical models assessing anti‑cancer efficacy linked to microbial modulation
- Structure‑activity relationship (SAR) studies to refine potency, selectivity, and pharmacokinetic properties
- Integrated safety profiling to ensure minimal off‑target effects on human cells